Roxana Mehran talks with Robert Harrington, the new Dean of Weill Cornell Medicine, about his move to New York and plans for ...

Ten years after learning their polygenic risk score, patients had fewer events—perhaps due to greater use of statin therapy.

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Nontraditional risk factors, particularly migraine with aura, play a major role in patients under 50 years old.

Not everyone is sold on the benefits of early ezetimibe use, especially given the modest effect seen in IMPROVE-IT.